| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.09 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.062 | 0.09 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |